IMMUNOLOGICAL PRECONDITIONS OF CONVERSION FROM NATALIZUMAB TO FINGOLIMOD
https://doi.org/10.21518/2079-701X-2017-0-80-83
Abstract
This article presents the results of the immunological profile of CD4+ T cells and Th17 cells and production of interleukin-17 (IL-17) in two groups of patients receiving treatment natalizumab and fingolimod. The results can underpin the justification for the preferred transfer of patients with relapsing-remitting multiple sclerosis after treatment by natalizumab to fingolimod.
About the Authors
E. V. Popova
Interregional Department of Disseminated Sclerosis (Municipal Clinical Hospital No. 24 of the Moscow Healthcare Department)
Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
PhD in medicine
M. V. Melnikov
Clinical Immunology Laboratory of State National Center Immunology Center of the Federal Medical and Biological Agency, Moscow
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
A. N. Boyko
Pirogov Russian National Research Medical University, Moscow
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
M. B. Paschenkov
Clinical Immunology Laboratory of State National Center Immunology Center of the Federal Medical and Biological Agency, Moscow
Russian Federation
MD
Russian Federation
MD
References
1. Kappos L, Kuhle J, Gass A, Achtnichts L and Radue E. Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future? Journal of Neurology, 2004, 251(S5): v57-v64. doi: 10.1007/s00415-004-1509-6.
2. Freedman M, Rush C. Severe, Highly Active, or Aggressive Multiple Sclerosis. CONTINUUM: Lifelong Learning in Neurology, 2016, 22: 761-784. doi:10.1212/con.0000000000000331.
3. Приложение. Критерии неэффективности терапии и отмены ПИТРС первой линии и замены на препараты второй линии. Журнал неврологии и психиатрии им. С.С. Корсакова, 2015, 115(8): 44-44. doi: 10.17116/jnevro20151158244.
4. Bengsch B, Seigel B, Flecken T, Wolanski J, Blum H and Thimme R. Human Th17 Cells Express High Levels of Enzymatically Active Dipeptidylpeptidase IV (CD26). The Journal of Immunology, 2012, 188(11): 5438-5447. doi: 10.4049/jimmunol.1103801.
5. Bossowski A, Moniuszko M, Idźkowska E, Dąbrowska M, Jeznach M, Sawicka B, Borysewicz-Sańczyk H, Bossowska A, Rusak M, BodzentaŁukaszyk A. Evaluation of CD4+CD161+CD196+ and CD4+IL-17+ Th17 cells in the peripheral blood of young patients with Hashimoto’s thy-roiditis and Graves’ disease. Pediatr Endocrinol Diabetes Metab., 2012, 18(3):9-95.
6. Попова Е.В., Мельников М.В., Бойко А.Н., Муругин В.В., Пащенков М.В. Вопросы тактики ведения больных с труднокурабльным ремиттирующим рассеянным склерозом. Медицинский совет. 2015, 10: 63-65. doi: http://dx.doi.org/10.21518/2079-701X-2015-10-63-65.
7. Sormani MP, Stefano N. Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy. J Neurol, 2014, 82: 1-2.
8. Попова Е.В., Ялымов А.А., Бойко А.Н., Давыдовская М.В., Кольяк Е.В., Трактирская О.В., Хачанова Н.В., Щур С.Г. Финголимод в лечении ремиттирующего рассеянного склероза: опыт применения в Московском городском центре рассеянного склероза. Медицинский совет, 2014, 5: 60-63. doi: http://dx.doi.org/10.21518/2079-701X-2014-5-60-63.
9. Brinkmann V, Davis M, Heise C et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem., 2002. 277: 21453-21457.
Review
For citations:
Popova EV, Melnikov MV, Boyko AN, Paschenkov MB. IMMUNOLOGICAL PRECONDITIONS OF CONVERSION FROM NATALIZUMAB TO FINGOLIMOD. Meditsinskiy sovet = Medical Council. 2017;(1S):80-83. (In Russ.) https://doi.org/10.21518/2079-701X-2017-0-80-83
Views:
728
Email this article 